Keratosis pilaris atrophicans. One heterogeneous disease or a symptom in different clinical entities?
نویسندگان
چکیده
منابع مشابه
Nilotinib-Induced Keratosis Pilaris
Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) that is approved for the treatment of imatinib-resistant chronic myeloid leukaemia expressing the Bcr-Abl mutation. Cutaneous adverse drug reactions occur more frequently in patients using this medication. We present a case of nilotinib-induced keratosis pilaris that did not have accompanying symptoms of alopecia or prurit...
متن کاملIs Alopecia a Clinical Symptom in Kawasaki Disease?
A 20-months-old infant was admitted with prolonged fever, bilateral non-purulent conjunctivitis, strawberry tongue, lip cracking and maculopapular rash. Left branch coronary aneurysm formation was detected in Color-Doppler echocardiography. The diagnosis was Kawasaki disease. After 6 weeks, he had alopecia totalis. Although, alopecia areata has been seen in Kawasaki disease, but alopecia totali...
متن کاملMotoneuron double discharges: only one or two different entities?
INTRODUCTION The firing behavior of spinal motoneurons is controlled by a complex interplay between the synaptic inputs that they receive and the intrinsic properties of motoneurons. In particular, the longlasting afterhyperpolarization which follows each motoneuron spike was found to be an important mechanism in the regulation of repetitive firing behavior (Kernell, 1965, 2006). As a result, m...
متن کاملTreatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial.
IMPORTANCE Keratosis pilaris (KP) is a common skin disorder of follicular prominence and erythema that typically affects the proximal extremities, can be disfiguring, and is often resistant to treatment. Shorter-wavelength vascular lasers have been used to reduce the associated erythema but not the textural irregularity. OBJECTIVE To determine whether the longer-wavelength 810-nm diode laser ...
متن کاملEpidermal Permeability Barrier in the Treatment of Keratosis Pilaris
Objectives. To evaluate and compare the efficacy, safety, hydrating properties, and tolerability of 10% lactic acid (LA) and 5% salicylic acid (SA) in the therapy of keratosis pilaris (KP). Material and Method. Patients with KP were randomized for treatment with either 10% LA or 5% SA creams being applied twice daily for 3 months. The patients were clinically assessed at baseline and after 4, 8...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Dermatology
سال: 1994
ISSN: 0003-987X
DOI: 10.1001/archderm.130.4.500